Understanding pathophysiological mechanisms of PCI-related AMI

The management of stable ischaemic heart disease continues to evolve with the recently presented ISCHEMIA trial demonstrating that revascularisation therapy (primarily percutaneous coronary intervention, PCI) does not reduce the risk of major adverse cardiac events in high risk stable angina patients with moderate-severe ischaemia [1]. Indeed, the ISCHEMIA trial reported more acute myocardial infarction (AMI) in the first 6  months after randomisation amongst those managed with PCI therapy as compared to those treated with optimal medical therapy alone.
Source: International Journal of Cardiology - Category: Cardiology Authors: Tags: Editorial Source Type: research